Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Hiroto InabaJolieke G van OosterwijkJohn Carl PanettaLie LiDaelynn R BuelowJames S BlachlySheila ShurtleffChing-Hong PuiRaul C RibeiroJeffrey E RubnitzStanley PoundsSharyn D BakerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The combination of crenolanib and sorafenib was tolerable with antileukemic activities and rare emergence of FLT3-TKD mutations, which warrants further investigation.